These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 34135201)
1. Study Protocol for a Multicenter, Open-Label, Single-Arm Study of Tranilast for Cardiomyopathy of Muscular Dystrophy. Matsumura T; Hashimoto H; Sekimizu M; Saito AM; Iwata Y; Asakura M; Kimura K; Tamura T; Funato M; Segawa K; Ogata K; Nakajima T Kurume Med J; 2021 Jul; 66(2):121-126. PubMed ID: 34135201 [TBL] [Abstract][Full Text] [Related]
2. Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label, multicenter study. Matsumura T; Hashimoto H; Sekimizu M; Saito AM; Motoyoshi Y; Nakamura A; Kuru S; Fukudome T; Segawa K; Takahashi T; Tamura T; Komori T; Watanabe C; Asakura M; Kimura K; Iwata Y Orphanet J Rare Dis; 2022 May; 17(1):201. PubMed ID: 35578298 [TBL] [Abstract][Full Text] [Related]
3. A Pilot Study of Tranilast for Cardiomyopathy of Muscular Dystrophy. Matsumura T; Matsui M; Iwata Y; Asakura M; Saito T; Fujimura H; Sakoda S Intern Med; 2018 Feb; 57(3):311-318. PubMed ID: 29093384 [TBL] [Abstract][Full Text] [Related]
4. Impact of the TRPV2 Inhibitor on Advanced Heart Failure in Patients with Muscular Dystrophy: Exploratory Study of Biomarkers Related to the Efficacy of Tranilast. Takahashi C; Oishi M; Iwata Y; Maekawa K; Matsumura T Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768491 [TBL] [Abstract][Full Text] [Related]
5. Reply to "The Effects of Tranilast on Cardiomyopathy in Becker Muscular Dystrophy Requires Profound Cardiac and Neurologic Evaluations". Matsumura T; Iwata Y; Asakura M Intern Med; 2018 Jul; 57(14):2101-2102. PubMed ID: 29491287 [No Abstract] [Full Text] [Related]
6. Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy. Iwata Y; Matsumura T Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31394715 [TBL] [Abstract][Full Text] [Related]
7. The Effects of Tranilast on Cardiomyopathy in Becker Muscular Dystrophy Requires Profound Cardiac and Neurologic Evaluations. Stöllberger C; Finsterer J Intern Med; 2018 Jul; 57(14):2099. PubMed ID: 29491311 [No Abstract] [Full Text] [Related]
8. ACE inhibition to slow progression of myocardial fibrosis in muscular dystrophies. Russo V; Papa AA; Williams EA; Rago A; Palladino A; Politano L; Nigro G Trends Cardiovasc Med; 2018 Jul; 28(5):330-337. PubMed ID: 29292032 [TBL] [Abstract][Full Text] [Related]
9. Novel inhibitor candidates of TRPV2 prevent damage of dystrophic myocytes and ameliorate against dilated cardiomyopathy in a hamster model. Iwata Y; Katayama Y; Okuno Y; Wakabayashi S Oncotarget; 2018 Mar; 9(18):14042-14057. PubMed ID: 29581825 [TBL] [Abstract][Full Text] [Related]
10. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977 [TBL] [Abstract][Full Text] [Related]
11. Production of TRPV2-targeting functional antibody ameliorating dilated cardiomyopathy and muscular dystrophy in animal models. Iwata Y; Wakabayashi S; Ito S; Kitakaze M Lab Invest; 2020 Feb; 100(2):324-337. PubMed ID: 31896817 [TBL] [Abstract][Full Text] [Related]
13. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. Dittrich S; Graf E; Trollmann R; Neudorf U; Schara U; Heilmann A; von der Hagen M; Stiller B; Kirschner J; Pozza RD; Müller-Felber W; Weiss K; von Au K; Khalil M; Motz R; Korenke C; Lange M; Wilichowski E; Pattathu J; Ebinger F; Wiechmann N; Schröder R; Orphanet J Rare Dis; 2019 May; 14(1):105. PubMed ID: 31077250 [TBL] [Abstract][Full Text] [Related]
14. Amelioration of diabetes-induced cognitive impairment by Transient Receptor Potential Vanilloid 2 (TRPV2) channel inhibitor: Behavioral and mechanistic study. Thapak P; Bishnoi M; Sharma SS Neurochem Int; 2020 Oct; 139():104783. PubMed ID: 32652268 [TBL] [Abstract][Full Text] [Related]
15. Plasma levels of brain natriuretic peptide as an index for evaluation of cardiac function in female gene carriers of Duchenne muscular dystrophy. Adachi K; Kawai H; Saito M; Naruo T; Kimura C; Mine H; Inui T; Kashiwagi S; Akaike M Intern Med; 1997 Jul; 36(7):497-500. PubMed ID: 9240500 [TBL] [Abstract][Full Text] [Related]
16. New approaches in the therapy of cardiomyopathy in muscular dystrophy. McNally EM Annu Rev Med; 2007; 58():75-88. PubMed ID: 17217326 [TBL] [Abstract][Full Text] [Related]
17. Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial. Raman SV; Hor KN; Mazur W; Cardona A; He X; Halnon N; Markham L; Soslow JH; Puchalski MD; Auerbach SR; Truong U; Smart S; McCarthy B; Saeed IM; Statland JM; Kissel JT; Cripe LH J Am Heart Assoc; 2019 Oct; 8(19):e013501. PubMed ID: 31549577 [TBL] [Abstract][Full Text] [Related]
18. Predictors of Death in Adults With Duchenne Muscular Dystrophy-Associated Cardiomyopathy. Cheeran D; Khan S; Khera R; Bhatt A; Garg S; Grodin JL; Morlend R; Araj FG; Amin AA; Thibodeau JT; Das S; Drazner MH; Mammen PPA J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042427 [TBL] [Abstract][Full Text] [Related]
19. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases. Rodrigues M; Yokota T Methods Mol Biol; 2018; 1828():31-55. PubMed ID: 30171533 [TBL] [Abstract][Full Text] [Related]
20. A trial of flunarizine in the treatment of Duchenne muscular dystrophy. Dick DJ; Gardner-Medwin D; Gates PG; Gibson M; Simpson JM; Walls TJ Muscle Nerve; 1986 May; 9(4):349-54. PubMed ID: 3520308 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]